GHP Investment Advisors Inc. Purchases 1,517 Shares of Pfizer Inc. (NYSE:PFE)

GHP Investment Advisors Inc. grew its position in shares of Pfizer Inc. (NYSE:PFE) by 12.6% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,523 shares of the biopharmaceutical company’s stock after buying an additional 1,517 shares during the quarter. GHP Investment Advisors Inc.’s holdings in Pfizer were worth $343,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Rialto Wealth Management LLC bought a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. bought a new position in shares of Pfizer during the 4th quarter worth approximately $27,000. Gould Capital LLC increased its stake in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $30,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on PFE. Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target for the company. UBS Group raised their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. The Goldman Sachs Group restated a “neutral” rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Stock Down 0.1%

Pfizer stock opened at $24.29 on Thursday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The firm has a market capitalization of $138.10 billion, a price-to-earnings ratio of 17.60, a P/E/G ratio of 0.88 and a beta of 0.57. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The firm has a 50 day simple moving average of $23.38 and a 200 day simple moving average of $24.87.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business’s revenue for the quarter was down 7.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.82 EPS. On average, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.08%. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.